French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases. 1 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
USA-based brain health biotech Mind Medicine (MindMed; Nasdaq: MNMD) announced the appointment of Stephanie Fagan as Chief Corporate Affairs Officer. 30 July 2024
Zymeworks has appointed Leone Patterson as executive vice president, and chief business and financial officer, effective September 1, 2024. 26 July 2024
The appointment of Dr Sicard comes at a time when the company has selected its lead candidate, DGX-01, a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in t 25 July 2024
Latigo Biotherapeutics, a privately-held US biotech focused on developing non-opioid pain medicines, has appointed Nima Farzan as chief executive. 23 July 2024
Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer as chief executive. 16 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
UK-based Mogrify, a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, has announced the appointment of Jonathan Appleby as chief scientific officer (CSO). 15 July 2024
Henry Pelish has continued his rise up the ranks at Nuvalent, a Boston-based biopharma focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. 11 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
USA-based drug conjugates (ADCs) developer Sutro Biopharma
has appointed Barbara Leyman, as chief business development officer, effective July 8, 2024. 10 July 2024